TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InnoCare Pharma Ltd. ( (HK:9969) ) has provided an announcement.
InnoCare Pharma Ltd. has announced a global strategic collaboration and license agreement with Zenas BioPharma for the development, manufacture, and commercialization of orelabrutinib and two other preclinical assets. This agreement grants Zenas exclusive rights in specific fields and territories, with InnoCare retaining certain rights. The deal, potentially exceeding $2 billion, includes upfront and milestone payments, along with royalties, indicating a significant impact on InnoCare’s operations and market positioning.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a biopharmaceutical company involved in the development and commercialization of innovative therapies for cancer and autoimmune diseases. Its primary products include orelabrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, which has gained significant market recognition in China, particularly in the field of hemato-oncology.
Average Trading Volume: 18,331,578
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.35B
Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.